References
- Stacul F, van der Molen AJ, Reimer P et al. Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines. Eur. Radiol. 21(12), 2527–2541 (2011).
- Sadat U, Usman A, Gillard JH, Boyle JR. Does ascorbic acid protect against contrast induced-acute kidney injury in patients undergoing coronary angiography-a systematic review with meta-analysis of randomized controlled trials. J. Am. Coll. Cardiol. (2013) (Epub ahead of print).
- Li Y, Liu Y, Fu L, Mei C, Dai B. Efficacy of short-term high-dose statin in preventing contrast-induced nephropathy: a meta-analysis of seven randomized controlled trials. PLoS ONE 7(4), e34450 (2013).
- Sadat U. Contrast-induced nephropathy: do statins offer protection? Curr. Opin. Cardiol. 26(4), 334–337 (2011).
- Dai B, Liu Y, Fu L, Li Y, Zhang J, Mei C. Effect of theophylline on prevention of contrast-induced acute kidney injury: a meta-analysis of randomized controlled trials. Am. J. Kidney Dis. 60(3), 360–370 (2012).
- Nitescu N, Ricksten S-E, Marcussen N et al. N-acetylcysteine attenuates kidney injury in rats subjected to renal ischaemia-reperfusion. Nephrol. Dial. Transplant. 21(5), 1240–1247 (2006).
- Naziroglu M, Yoldas N, Uzgur EN, Kayan M. Role of contrast media on oxidative stress, Ca(2+) signaling and apoptosis in kidney. J. Membr. Biol. 246(2), 91–100 (2013).
- Heyman SN, Rosen S, Khamaisi M, Idee JM, Rosenberger C. Reactive oxygen species and the pathogenesis of radiocontrast-induced nephropathy. Invest. Radiol. 45(4), 188–195 (2010).
- Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N. Engl. J. Med. 343(3), 180–184 (2000).
- Stenstrom DA, Muldoon LL, Armijo-Medina H et al. N-acetylcysteine use to prevent contrast medium-induced nephropathy: premature Phase III trials. J. Vasc. Interv. Radiol. 19(3), 309–318 (2008).
- Gonzales DA, Norsworthy KJ, Kern SJ et al. A meta-analysis of N-acetylcysteine in contrast-induced nephrotoxicity: unsupervised clustering to resolve heterogeneity. BMC Med. 5, 32 (2007).
- Hoffmann U, Fischereder M, Kruger B, Drobnik W, Kramer BK. The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J. Am. Soc. Nephrol. 15(2), 407–410 (2004).
- Macedo E, Abdulkader R, Castro I, Sobrinho AC, Yu L, Vieira JM Jr. Lack of protection of N-acetylcysteine (NAC) in acute renal failure related to elective aortic aneurysm repair-a randomized controlled trial. Nephrol. Dial. Transplant. 21(7), 1863–1869 (2006).
- Vaitkus PT, Brar C. N-acetylcysteine in the prevention of contrast-induced nephropathy: publication bias perpetuated by meta-analyses. Am. Heart J. 153(2), 275–280 (2007).
- Goldenberg I, Shechter M, Matetzky S et al. Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. A randomized controlled trial and review of the current literature. Eur. Heart J. 25(3), 212–218 (2004).
- Sun Z, Fu Q, Cao L, Jin W, Cheng L, Li Z. Intravenous N-acetylcysteine for prevention of contrast-induced nephropathy: a meta-analysis of randomized, controlled trials. PLoS ONE 8(1), e55124 (2013).
- O’Sullivan S, Healy DA, Moloney MC, Grace PA, Walsh SR. The role of N-acetylcysteine in the prevention of contrast-induced nephropathy in patients undergoing peripheral angiography: a structured review and meta-analysis. Angiology 64(8), 576–582 (2012).
- ACT-Investigators. Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized Acetylcysteine for Contrast-induced nephropathy Trial (ACT). Circulation 124(11), 1250–1259 (2011).
- Weisbord SD, Gallagher M, Kaufman J et al. Prevention of contrast-induced AKI: a review of published trials and the design of the prevention of serious adverse events following angiography (PRESERVE) trial. Clin. J. Am. Soc. Nephrol. 8(9), 1618–1631 (2013).